These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17000285)

  • 1. Positron emission tomography predicts survival in malignant pleural mesothelioma.
    Flores RM; Akhurst T; Gonen M; Zakowski M; Dycoco J; Larson SM; Rusch VW
    J Thorac Cardiovasc Surg; 2006 Oct; 132(4):763-8. PubMed ID: 17000285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
    Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
    J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
    Flores RM; Akhurst T; Gonen M; Larson SM; Rusch VW
    J Thorac Cardiovasc Surg; 2003 Jul; 126(1):11-6. PubMed ID: 12878934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
    Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PET in the surgical management of malignant pleural mesothelioma.
    Flores RM
    Lung Cancer; 2005 Jul; 49 Suppl 1():S27-32. PubMed ID: 15950796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
    Nowak AK; Francis RJ; Phillips MJ; Millward MJ; van der Schaaf AA; Boucek J; Musk AW; McCoy MJ; Segal A; Robins P; Byrne MJ
    Clin Cancer Res; 2010 Apr; 16(8):2409-17. PubMed ID: 20371686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. eComment: What is the best way to diagnose and stage malignant pleural mesothelioma?
    Cafarotti S; Porziella V; Margaritora S; Granone P
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):811. PubMed ID: 21555444
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
    Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
    J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
    Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
    J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
    Kaira K; Serizawa M; Koh Y; Takahashi T; Hanaoka H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
    Eur J Cancer; 2012 May; 48(8):1244-54. PubMed ID: 22330319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE; Subramaniam RM; Peller PJ; Aughenbaugh GL; Nichols Iii FC; Aubry MC; Jett JR
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
    Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
    J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
    J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.